Continuation of same programmed death-1 inhibitor regime beyond progression is a novel option for advanced gastric cancer
Continuation of the same type of PD-1 inhibitor regime in IBP shows clinical benefits and represents a promising therapeutic approach.
Authors
- Zhanjun Guo (ORCID: https://orcid.org/0000-0002-5111-5444)
- Qingyi Liu (ORCID: https://orcid.org/0009-0005-1180-966X)
- Tianhang Zhang (ORCID: https://orcid.org/0000-0002-7939-5302)
- Siqi Wang (ORCID: https://orcid.org/0000-0002-2179-620X)
- Yuanyuan Jia (ORCID: https://orcid.org/0009-0005-5560-5060)
- Shasha Zhang (ORCID: https://orcid.org/0000-0003-3431-7615)
- Fang Ding (ORCID: https://orcid.org/0000-0002-3278-2073)
- Jiasong Li (ORCID: https://orcid.org/0000-0002-8828-1729)
Institutions
- Hebei Medical University (CN)
- Fourth Hospital of Hebei Medical University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1186/s12885-024-13063-2
- Citations
- 2
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.84